The abbreviations used are: EGFR, epidermal growth factor receptor; DMEM, Dulbecco's modified Eagle's medium; PBS, phosphate-buffered saline; FBS, foetal bovine serum; TGF-, Transforming Growth Factor-beta; Stat3, Signal Transducer and Activator of Transcription 3; Smad, Sma-and Mad-related protein. 
Introduction
Growth factor and cytokine signaling networks control many aspects of cell behaviour such as proliferation, survival, migration, invasive capabilities, transformation and differentiation. In normal cells, these complex signaling pathways are tightly regulated.
Alterations of these signals are often found to cause, directly or indirectly, tumor formation.
Transforming Growth Factor-(TGF-) and Epidermal Growth Factor (EGF) signaling pathways are both independently implicated as key regulators in tumor formation and as such they are potential therapeutic targets [1] [2] [3] [4] .
Ever since its discovery, EGFR has been intimately associated with cancer. Indeed, the cDNA of EGF receptor was first cloned from the human A431 carcinoma cell line, which over expresses the receptor protein [5] [6] [7] [8] . Subsequently, the involvement of the EGFR in many human cancers has been established in cancers of the head&neck (90%), brain (30%), breast (30-50%), bladder (30-90%), stomach (30-70%), lung (45%), ovarian (30-80%) and prostate (10%) 9, 10 . A number of studies further demonstrated that overexpression of EGFR or its tumor associated mutant forms resulted in tumor transformation in vitro and enhanced tumor growth in vivo, suggesting a causal effect of the elevation of the EGFR expression levels in carcinogenesis 11 . That role of EGFR in carcinogenesis led to the development and evaluation of EGFR blocking agents for cancer treatment 1 . Two EGFR-targeted approaches have been explored: one using monoclonal antibodies (mAbs) targeting its extracellular domain, and the other using small-molecular tyrosine kinase inhibitors (TKIs) targeting its intracellular tyrosine kinase 1, 12, 13 . A combination of the two or with chemotherapeutic treatment has also been evaluated 1 . The successful development of EGFR-specific TKIs gave rise to high hope that EGFR-blocking reagents could be the next generation of "magic bullets" in treating human cancers 14 .
More than 20 phase II and III clinical trials targeting EGFR have been conducted, some are still active, on many cancer types, including cancers of the head&neck, colorectal, glioma, prostate, NSCL(non-small cell lung) and other types of cancers, with current trials focusing on NSCL cancers 1, 15, 16 . However, the patient response rate varied greatly from almost no response to over 50%, while the improvement on overall patient survival is uncertain 1, 17 .
While monotherapy targeting EGFR delivered some responses, early trials did not show improvement in combination therapy 1, 17 . The reasons for their apparent lack of benefit when used in combination therapy are unclear. It is suspected that different administration schedules may be required 21 . Further research is necessary to establish their mechanism of action.
Identification of accurate biomarkers may be needed to identify appropriate patients 1, 18 .
In normal cells, EGFR is expressed at relatively low levels (~10 4 TGF-regulates a wide range of cellular processes including cell proliferation, differentiation, migration, organization and death 3 . As one of the most potent inhibitors of normal cell growth, the loss of growth inhibitory responses to TGF-is often observed in cancer cells 22, 23 . It is widely accepted that TGF-is a tumor suppressor, given the frequent occurrence of many types of tumors in mice with disruption of TGF-or its signaling components by gene targeting and many types of human cancers containing loss-of-function mutation of TGF-signaling components 3, 24 .
Biological responses to TGF-are mediated mainly by the type I (T RI) and II (T RII) transmembrane cell surface receptors 4, 25 which contain cytoplasmic domains with serine/threonine kinase activity. TGF-ligands bind T RI and T RII thereby triggering phosphorylation and activation of T RI. The activated ligand-receptor complex then binds and phosphorylates through T RI the intracellular signaling molecules Smad2 and Smad3 4, 25, 26 . Once phosphorylated these regulatory Smads (R-Smad) form complexes with Smad4 (also called DPC4 for deleted in pancreatic carcinoma locus 4) and translocates into the nucleus. In the nucleus, they associate with transcription factors to form transcriptionally active DNA complexes 4, 25, 26 .
TGF-signaling can be negatively regulated at multiple levels in and out side the target cells 4 : secreted molecules such as decorin binds directly to TGF-ligands and neutralize their biological activity; the transmembrane protein BAMB1 sequesters ligand from binding to T RI; FKBP12 blocks receptor phosphorylation; the E3 ubiquitin ligase Smurf1 degrades RSmads and T R following binding to Smad7, while Smad7 directly competes with Smad2/3 for binding to T RI.
The tight regulation of TGF-signaling pathway at every step is critical in homeostasis, since any perturbation of the pathway in vivo appear to result in cancer forming in mice.
Deletion of one copy of Smad4 or TGF-1 gene resulted in gastric tumor formation in mice 27, 28 as well as mice lacking the gene encoding the RUNX3 transcription factor 29 .
Intriguingly, the transcription factor RUNX3 is a target gene for TGF-signaling and the gastric epithelium of RUNX3 -/-mice is desensitized to TGF--dependent growth suppression.
Consequently, the mice also gave rise to gastric tumor formation 29 . Perturbation of TGFsignaling by expressing a dominant negative form of T RII (DN-T RII) 30 or the negative regulator Smad7 31 as a transgene in mice also led to various forms of tumor formation. It remains to be answered whether the TGF-signaling pathway is so fundamental in maintaining homeostasis that not only its direct disruptions, but also other oncogenic signals acting through the impairment of TGF-signaling, leads to tumor formation.
Stat signaling pathways were originally delineated in the context of normal cytokine receptors such as interferon (IFN) and interleukin-6 (IL-6) receptors 32, 33 . Evidence for a role of Stat3 in tumor transformation was provided by a constitutively activated mutant form, Stat3C, which was found to transform fibroblasts in culture, allowing them to form tumors in mice 34 . The first direct links between Stat3 and human cancer came from the findings that constitutive Stat3 activity is required for the growth of head&neck cancer cells and multiplemyeloma cells 35, 36 . Subsequently, Stat3 activation has been detected at high frequency in diverse human cancer cell lines and tissues of blood, breast, head&neck, skin, lung and prostate 6 .
We have recently discovered 37 Here we establish a novel EGFR-Stat3-Smad7-TGF-signaling molecular axis where tumor-associated over-expression of EGFR in epithelial cells results in specifically the sustained hyperactivation of Stat3, which induces Smad7 expression, compromising the TGF-'s cytostatic regulation of epithelium and consequent tumor formation.
Results

Over-expression of EGFR inhibits TGF-signaling.
A previous study showing that aberrant IL-6/gp130 signaling caused a desensitization in TGF-response 37 , led us to hypothesize that EGFR signaling could also mediate a similar outcome. Five human cell lines (A431, HN5, 293T, 293T-EGFR and A549 cells) with varying EGFR expression levels were used ( Fig. 1a) , to determine whether EGFR activation effected TGF-signaling. The Smad3 luciferase reporter construct, pCAGA 12 -luc was transiently transfected into those cell lines to quantitatively determine TGF-signaling sensitivity. Stimulation with TGF-activated pCAGA 12 -luc activity in all 5 cell lines used (Fig. 1b) . Interestingly, this increased pCAGA 12 luc activity was significantly reduced in EGFR over-expressing cells (A431, HN5 and 293T-EGFR), but not in the low EGFR expressing cells lines (293T and A549) when cells were treated with EGF ( Fig. 1b) , suggesting that EGF inhibited pCAGA 12 -luc activity in cells with high levels of EGFR expression.
As EGF inhibited Smad3 reporter activity in cell lines expressing high EGFR levels, we next examined whether EGF had similar effects on Smad2 phosphorylation and localization.
As expected, TGF-treatments resulted in increased Smad2 phosphorylation in all 5 cell lines tested ( Fig. 1c) . EGF however, clearly reduced the TGF--mediated phospho-Smad2 levels in A431, HN5 and 293T-EGFR cells, albeit these levels were still greater than basal levels ( Fig.   1c ). In contrast, EGF induced no detectable difference in phospho-Smad2 levels in 293T and A549 cells (Fig. 1c) . Consequently, EGF treatment caused a marked decrease of Smad2 nuclear translocalisation by TGF-such as in A431 cells (Fig. 1d ).
To confirm that EGFR activation was responsible for the observed desensitization of the TGF-signaling, AG1478, a specific inhibitor of EGFR 38 was used. Treatment with AG1478 dramatically reduced both basal and ligand stimulated phospho-EGFR in A431, HN5
and 293T-EGFR cells (Fig. 1e) . It had no effect on the TGF-reporter activity in the normal-EGFR expressing 293T cell line (Fig. 1f) . However, the EGF-mediated reduction of the TGFreporter activity was reversed when A431, HN5 and 293T-EGFR cells were co-treated with AG1478 ( Fig. 1f) , confirming that activation of over-expressed EGFR mediates the desensitization of the TGF-signaling.
Finally, to determine whether EGFR blockade re-sensitized cells to the inhibitory effects of TGF-, the EGFR over-expressing human head&neck tumor cells HN5 were treated with TGF-with or without AG1478 and assessed for [ 
EGF-Mediated Inhibition of the TGF-pathway is not dependent on PI3-K and MEK
Signaling. Two of the most documented signaling pathways activated upon EGFR phosphorylation are the Ras-MAPKs and the PI3K-Akt pathways. To examine whether these pathways were involved in the desensitization of TGF-signaling, we used pharmacological inhibitors to block either MEK (U0126) or PI3K (LY294002) activity without effecting phospho-EGFR levels (Fig. 2a, 2b ). Unlike the EGFR inhibitor AG1478, neither the MEK inhibitor U0126 nor the PI3K inhibitor LY294002 re-sensitized the TGF-reporter activity in the EGFR over-expressing HN5 and 293T-EGFR cells (Fig. 2c, d ). These results suggest that the EGF-mediated inhibition of the TGF-pathway is not dependent on MEK and PI3K
signaling.
Over-expression of EGFR mediates specifically sustained Stat3 phosphorylation and transcriptional activity. As we had previously shown that sustained Stat3 activation results in the desensitization of TGF-signaling in the IL-6/gp130 signaling system 37 , we next set out to determine whether EGF could lead to Stat3 activation. While EGF-stimulation resulted in increased phospho-EGFR, phospho-Erk1/2 and phospho-Akt levels in all 5 cell lines used (A431, HN5, 293T, 293T-EGFR and A549) without changes to total protein levels, phosphorylation of Stat3 was observed in only the EGFR over-expressing cell lines, (A431, HN5 and 293T-EGFR) (Fig. 3a) . Furthermore, this EGFR over-expression-specific Stat3 activation was sustained throughout the duration of a 480 min time-course experiment ( Fig.   3b ). In fact the specific sustained Stat3 phosphorylation correlated with an increase in Stat3 transcriptional activation as measured by the luciferase promoter activity using the pAPRE-luc reporter construct in EGFR over-expression cells (Fig. 3c ). There was minimal Stat3 reporter activation in the cells expressing normal or low levels of EGFR (293T and A529) (< 2-fold;
data not shown). Using the EGFR inhibitor AG1478, it was further confirmed that Stat3 phosphorylation and transcriptional activity were indeed mediated by EGFR in all the cell lines examined (Fig. 3d) . Finally, using the small molecular inhibitors to MEK and PI3K, the EGFR over-expression mediated Stat3 phosphorylation and transcriptional activity were determined to be independent of the MEK and PI3K pathways ( Supplementary Fig. 1 ). Taken
together, these results demonstrate that over-expression of EGFR mediates specifically sustained Stat3 phosphorylation and transcriptional activity.
EGFR mediated inhibition of the TGF-signaling is Stat3-dependent. To verify
conclusively that Stat3 mediates desensitization of the TGF-signaling, we knocked down Stat3 protein expression by siRNA (Fig. 4a) . In both A431 and HN5 cells the activity of the TGF-reporter pCAGA 12 -luc was increased when the endogenous Stat3 levels were knocked down ( Fig. 4b) (Fig. 5a) . Conversely, the pSmad7-luc promoter activity was significantly reduced when A431 or HN5 cells were treated with the EGFR inhibitor AG1478 (Fig. 5b) , demonstrating that Smad7 promoter activity can be regulated by EGFR activation.
Consequently, the Smad7 protein levels were decreased when EGFR activity is blocked by its inhibitor AG1478 (Fig. 5b) . Furthermore, both the Smad7 promoter activity and Smad7 protein expression were reduced when the Stat3 expression levels were knocked down (Fig.   5c ). These data demonstrate that up-regulation of Smad7 protein levels in EGFR overexpressing tumor cells is through the Stat3 mediated Smad7 promoter activation. To determine whether EGFR-Stat3 mediated desensitization of TGF-b signaling is due to increased Smad7 expression, we use Smad7 siRNA to knockdown its expression (Fig. 5d) .
Indeed, in both A431 and HN5 tumor cells, Smad7 knockdown largely restored the TGFreporter activity when EGFR is activated by EGF treatment (Fig. 5e ). Of note, the reporter activity in the absence of EGF treatment is also vastly increased by Smad7 knockdown, confirming the effect of the basal Smad7 expression increase in EGFR over-expressing cells, which can be reduced by EGFR inhibitor treatment (Fig. 5b) . Importantly, Smad7
knockdown, like Stat3 knockdown, restored HN5 tumor cell growth inhibitory sensitivity to TGF- (Fig. 5f ).
Discussion
Ever since its discovery as one of the first receptor tyrosine kinases, EGFR and its signaling have been studied extensively. Many downstream pathways have been identified, but little is known about the difference between the normal and tumorigenic signals transduced from EGFR. It was presumed that the two main downstream pathways, Ras-MAPK and PI3K-Akt were responsible for EGFR-driven tumor growth. However, it has been difficult to detect the different mode of their activation between normal and tumor cells. At best, less than 10% elevation of MAPK activation by a constitutively active EGFR ( 2-7EGFR) 39 was proposed to explain its tumorigenicity. Yet, these downstream signals have been employed to measure the efficacy of EGFR inhibition in cancer treatment [40] [41] [42] . The identification of Stat3 here as a molecule specifically and persistently activated by the overexpressed and tumor-associated EGFR but not by EGFR expressed at normal levels reveals a critical signaling difference by EGFR between normal and tumor cells.
In both the normal and tumor cells, MAPK (Erk1/2) and Akt activation by EGFR are rapid and transient (Fig. 3) , regardless of the levels of EGFR expression. In contrast, low levels of EGFR do not activate Stat3 while only high levels of EGFR are capable of Stat3 activation. Surprisingly, Stat3 activation by high levels of EGFR is slower than the Erk1/2 or Akt activation (Fig. 3 ). Furthermore, the high level of EGFR-mediated Stat3 activation is persistent, unlike the transient nature of Erk1/2 and Akt activation. This is in direct contrast to cytokines such as IL-6 and IL-11 which mediated Stat3 activation rapidly and transiently 37, 43 .
Our previous work demonstrated in both animal models and human tissues that persistent Stat3 activation leads to stomach epithelial hyper-proliferation. It becomes clear in recent years that Stat3 is an oncogene and its activation is prevalent in many human cancers 34, 44, 45 .
Unlike many other oncogenes, there is no genetic evidence of gain-of-function mutation. The observation that the tumor-associated over-expressed EGFR activates Stat3 persistently identifies EGFR as an upstream molecular cause of Stat3 activation physiologically.
The tumorigenic consequence of the persistent Stat3 activation at least is partially mediated through the desensitization of TGF-signaling via its negative regulator Smad7 expression in stomach epithelium 37 . Indeed, EGFR-mediated Stat3 activation also results in the desensitization of TGF-signaling in many cell lines with EGFR over-expression. More importantly, in the head&neck tumor cell line with high levels of EGFR, HN5, there is a loss of cytostatic/growth inhibitory regulation by TGF- (Fig.1) , which can be reversed by blocking either EGFR or Stat3 activation ( Fig. 1 and 4) . Restoration of TGF-signaling can also be achieved in those cell lines by knockdown of Smad7 expression ( . We have not seen any desensitization of TGF-signaling mediated by MAPKs (Erk1/2) in cells expressing either high or low levels EGFR (Fig. 3) . At least in the context of stomach epithelium, Stat1 did not cause de-sensitization of TGF-signaling 37 . Both here and our previous work 37 identify Stat3 as a key mediator of loss of TGF-cytostatic regulation through signaling pathway cross-talk.
In early tumor development where tumor growth and expansion are dominant, TGF-acts as a tumor suppressor while it promotes invasion in late stages of tumor progression.
Importantly, TGF-signaling may be necessary for the late tumor invasion, best demonstrated in colon tumor development where deletions or mutations in the TGFsignaling pathway gave rise to a better prognosis compared to patients with colon cancers with intact TGF-signaling 51, 52 . and 293T-EGFR cell lines were maintained in RPMI medium. All media contained 10%
Materials and Methods
Antibodies and reagents
foetal bovine serum (FBS), 2 mM glutamine, 100U/ml penicillin and 100 μg/ml streptomycin.
Cells were incubated in a humidified atmosphere of 90% air and 10% CO 2 at 37 C.
Western blot analysis Cells were lysed in a lysis buffer (50mM Tris (pH 7.4), 150mM
NaCl, 1% Triton-X-100, 50mM NaF, 2mM MgCl 2 , 1mM Na 3 VO 4 and protease inhibitor cocktail (Roche)) and clarified by centrifugation (13, Cells were then lysed and assessed for luciferase activity and expressed as outlined in Fig. 1b . 
